Zealand Pharma AS (XTER:22Z) E10: €0.00 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XTER:22Z Zealand Pharma AS XTER:22Z
45 GF Score
Price €41.21
! 7 Warning Signs
View Full Analysis

What is Zealand Pharma AS E10?

Zealand Pharma AS XTER:22Z 45 E10 is €0.00 as of Jun. 2026. GuruFocus rates XTER:22Z with a GF Score™ of 45/100. The stock has 7 warning signs investors should review.

Note: As E10 is a main component used to calculate Shiller PE Ratio. If the month end stock price for this stock is zero, result may not be accurate due to the exchange rate between different shares and the data will not be stored into our database. Selected historical data showed in the calculation sectione below is only for demostration purpose.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Zealand Pharma AS's adjusted earnings per share data for the three months ended in Jun. 2026 was €7.401. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €0.00 for the trailing ten years ended in Jun. 2026.

During the past 3 years, the average E10 Growth Rate was 30.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Zealand Pharma AS was 30.30% per year. The lowest was -43.60% per year. And the median was -24.65% per year.

As of today (2026-09-02), Zealand Pharma AS's current stock price is €41.21. Zealand Pharma AS's E10 for the quarter that ended in Jun. 2026 was €0.00. Zealand Pharma AS's Shiller PE Ratio of today is .

During the past 13 years, the highest Shiller PE Ratio of Zealand Pharma AS was 167.17. The lowest was 142.42. And the median was 153.04.


Zealand Pharma AS  (XTER:22Z) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

During the past 13 years, the highest Shiller P/E Ratio of Zealand Pharma AS was 167.17. The lowest was 142.42. And the median was 153.04.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Zealand Pharma AS E10 Related Terms


Zealand Pharma AS E10 Historical Data

* Premium members only.

The historical data trend for Zealand Pharma AS's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zealand Pharma AS E10 Chart

Zealand Pharma AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Zealand Pharma AS Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

XTER:22Z vs VRTX, REGN, MRNA: E10 Comparison

For the Biotechnology subindustry, Zealand Pharma AS's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zealand Pharma AS Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zealand Pharma AS's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Zealand Pharma AS's Shiller PE Ratio falls into.


XTER:22Z
45GF Score
Zealand Pharma AS XTER:22Z
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zealand Pharma AS E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Zealand Pharma AS's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=7.401/333.9520*333.9520
=7.401

Current CPI (Jun. 2026) = 333.9520.

Zealand Pharma AS Quarterly Data

per share eps CPI Adj_EPS
201609 -0.173 241.428 -0.239
201612 0.259 241.432 0.358
201703 -0.138 243.801 -0.189
201706 -0.496 244.955 -0.676
201709 -0.203 246.819 -0.275
201712 -0.488 246.524 -0.661
201803 -0.426 249.554 -0.570
201806 -0.482 251.989 -0.639
201809 4.016 252.439 5.313
201812 -0.570 251.233 -0.758
201903 -0.553 254.202 -0.726
201906 -0.580 256.143 -0.756
201909 -0.461 256.759 -0.600
201912 -0.726 256.974 -0.943
202003 -0.666 258.115 -0.862
202006 -0.211 257.797 -0.273
202009 -0.774 260.280 -0.993
202012 -1.301 260.474 -1.668
202103 -0.777 264.877 -0.980
202106 -0.924 271.696 -1.136
202109 -0.620 274.310 -0.755
202112 -0.873 278.802 -1.046
202203 -0.694 287.504 -0.806
202206 -1.483 296.311 -1.671
202209 -0.431 296.808 -0.485
202212 -0.906 296.797 -1.019
202303 -0.505 301.836 -0.559
202306 -0.739 305.109 -0.809
202309 0.165 307.789 0.179
202312 -0.617 306.746 -0.672
202403 -0.498 312.332 -0.532
202406 -0.626 314.175 -0.665
202409 -0.506 315.301 -0.536
202412 -0.552 315.605 -0.584
202503 -0.635 319.799 -0.663
202506 14.156 322.561 14.656
202509 -0.770 324.800 -0.792
202512 -0.711 324.054 -0.733
202603 -0.747 330.213 -0.755
202606 7.401 333.952 7.401

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of €0.00 mean?
Zealand Pharma AS (XTER:22Z) has a E10 of €0.00 as of Jun. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Zealand Pharma AS and its competitors.
Is Zealand Pharma AS's E10 too high?
Zealand Pharma AS's current E10 is €0.00. Overall, Zealand Pharma AS has a GF Score™ of 45/100, reflecting its overall financial health beyond just this single metric.
How does Zealand Pharma AS's E10 compare to VRTX and REGN?
Zealand Pharma AS's E10 of €0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Zealand Pharma AS and its competitors. Zealand Pharma AS's current E10 is €0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zealand Pharma AS stock overvalued right now?
Zealand Pharma AS (XTER:22Z) has a current E10 of €0.00. The current E10 is €0.00. Zealand Pharma AS's overall GF Score™ is 45/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Zealand Pharma AS (XTER:22Z), the current E10 is €0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Zealand Pharma AS Business Description

Address Sydmarken 11, Soborg, DNK, DK-2860
Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.
45GF Score

Get the complete analysis for XTER:22Z

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€41.21
Price